(Q33945171)

English

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

based on heuristic

inferred from title

Jean-Michel Molina

12

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Constance Delaugerre

3

object named as

Constance Delaugerre

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Sébastien Gallien

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Joséphine Braun

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Isabelle Charreau

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jacques Reynes

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

François Jeanblanc

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Renaud Verdon

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Pierre de Truchis

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Thierry May

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Isabelle Madelaine-Chambrin

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jean-Pierre Aboulker

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

EASIER ANRS 138 Study Group

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

28 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Journal of Antimicrobial Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

2099-2106

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

A case of rhabdomiolysis associated with raltegravir use.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Hepatic profile analyses of tipranavir in Phase II and III clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKR269

21 January 2018

Identifiers

10.1093/JAC/DKR269

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33945171&oldid=1586209722"